Our observations agree with the results of previous studies showing that basal phenotypes are associated with higher microvascular density and microvessel proliferation relative to non‐basal or luminal phenotypes in breast cancer.[64, 65, 66, 67] In terms of responses to normalizing interventions, targeting TGFβ in vascularized tumoroid models appears to be a successful strategy to improve drug delivery, particularly with TCs lacking EGFR (MCF7, SKBR3, Patient 1, and Patient 4). This evidence concerns the gene EGFR and breast cancer.